nelfinavir
nfv
aspartyl
proteas
inhibitor
numer
effect
human
cell
impart
attract
antitumor
properti
nfv
also
shown
vitro
inhibitori
activ
human
herpesvirus
hhv
given
appar
absenc
aspartyl
proteas
encod
hhv
investig
mechan
action
nfv
herp
simplex
viru
type
cultur
cell
select
resist
nfv
achiev
despit
multipl
passag
drug
pressur
nfv
significantli
affect
level
express
late
gene
product
normal
number
viral
particl
appear
produc
nfvtreat
cell
electron
microscopi
remain
within
cytoplasm
often
control
nfv
inhibit
activ
serin
proteas
could
antivir
activ
attribut
inhibit
akt
phosphoryl
nfv
found
decreas
glycosyl
viral
glycoprotein
b
c
result
aberr
subcellular
local
consist
induct
endoplasm
reticulum
stress
unfold
protein
respons
nfv
result
demonstr
nfv
caus
alter
glycoprotein
matur
egress
like
act
one
host
cell
function
import
hhv
replic
human
herpesviru
hhv
infect
ubiquit
respons
substanti
morbid
mortal
worldwid
particularli
among
peopl
infect
human
immunodefici
viru
hiv
herp
simplex
viru
hsv
cytomegaloviru
cmv
infect
recurr
difficult
treat
hiv
coinfect
individu
moreov
genit
hsv
infect
associ
greater
risk
hiv
acquisit
transmiss
progress
diseas
epsteinbarr
viru
infect
caus
common
aidsdefin
malign
kaposi
sarcoma
nonhodgkin
lymphoma
respect
although
greatli
reduc
effect
antiretrovir
therapi
art
complic
hhv
infect
remain
among
common
medic
problem
peopl
infect
hiv
worldwid
current
avail
antivir
drug
treat
prevent
complic
hhv
infect
directli
indirectli
target
viral
polymeras
drug
one
import
limit
includ
select
drugresist
viral
mutant
signific
toxic
andor
poor
bioavail
requir
intraven
administr
exampl
treatment
acyclovirresist
hsv
ganciclovirresist
cmv
infect
requir
use
intraven
foscarnet
cidofovir
associ
nephrotox
new
agent
effect
hhv
infect
need
safe
oral
bioavail
high
barrier
resist
nelfinavir
nfv
firstgener
hiv
aspartyl
proteas
inhibitor
recent
found
block
product
multipl
hhv
furthermor
also
potent
antitumor
antiangiogen
properti
clinic
trial
ongo
evalu
nfv
treatment
sever
cancer
mechan
nfv
act
tumor
cell
multifactori
includ
inhibit
cellular
proteas
akt
activ
nf
b
signal
well
induct
endoplasm
reticulum
er
stress
unfold
protein
respons
upr
autophagi
contrast
aspartyl
proteas
requir
hiv
matur
hhv
util
serin
proteas
gene
product
open
read
frame
orf
hypothes
nfv
inhibit
hhv
replic
act
viral
proteas
furthermor
specul
nfv
act
nonproteas
viral
target
would
improb
antivir
activ
like
due
one
effect
host
cell
could
impair
effici
viral
replic
therefor
investig
mechan
action
nfv
attempt
identifi
host
cell
viral
target
drug
vitro
human
fibroblast
hf
cultiv
dulbecco
modifi
eagl
medium
dmem
gibco
contain
fetal
bovin
serum
fb
unit
per
ml
penicillin
g
g
per
ml
streptomycin
penstrep
maintain
c
humidifi
co
atmospher
previous
describ
cell
maintain
dmem
supplement
fb
penstrep
strain
f
gift
keith
jerom
fred
hutchinson
cancer
research
center
drug
nfv
indinavir
idv
obtain
aid
research
refer
reagent
program
divis
aid
niaid
nih
nfv
solubil
dimethyl
sulfoxid
dmso
idv
acyclovir
sigmaaldrich
solubil
water
primari
antibodi
use
follow
mous
monoclon
antihsv
gb
virusi
mous
monoclon
gc
clone
abcam
rabbit
polyclon
cell
signal
technolog
mous
monoclon
anti
actin
antiflag
monoclon
antiha
monoclon
antibodi
clone
sigmaaldrich
western
blot
secondari
antibodi
use
peroxidaseconjug
affinipur
f
ab
fragment
goat
antimous
igg
h
l
peroxidaseconjug
affinipur
f
ab
fragment
goat
antirabbit
igg
h
l
jackson
immunoresearch
secondari
antibodi
immunofluoresc
alexafluor
f
ab
fragment
goat
antimous
igg
h
l
alexafluor
f
ab
fragment
goat
antirabbit
igg
h
l
life
technolog
blot
biotinyl
lectin
use
eastern
blot
vector
laboratori
inc
follow
peanut
agglutinin
pna
ricinu
communi
agglutinin
rca
wheat
germ
agglutinin
wga
concanavalin
cona
total
cellular
protein
g
load
per
lane
separ
sdspage
transfer
pvdf
membran
membran
block
bsa
trisbuff
salin
tbst
incub
g
lectinml
block
buffer
hour
wash
three
time
tbst
incub
hour
horseradishperoxidaseconjug
avidin
vector
lab
gml
tbst
blot
wash
three
time
tbst
follow
avidin
incub
detect
perform
use
enhanc
chemiluminesc
method
pierc
ecl
plu
hf
infect
moi
hour
c
incub
c
either
nfv
acv
drug
day
cell
lyse
four
passag
made
group
viru
harvest
freezethaw
cycl
follow
addit
nonfat
milk
viru
titer
determin
plaqu
assay
previous
describ
proteas
activ
assay
effect
nfv
matur
proteas
activ
assay
transfect
cell
vector
express
proteas
ntermin
amino
acid
orf
gene
product
well
two
substrat
capsid
scaffold
protein
amino
acid
orf
gene
product
fulllength
product
catalyt
inact
mutant
fulllength
proteasescaffold
protein
transcript
amino
acid
orf
gene
product
proteas
code
sequenc
contain
ntermin
ha
tag
substrat
contain
ntermin
flag
tag
vector
synthes
blue
heron
biotech
llc
substrat
express
alon
combin
proteas
presenc
nfv
vehicl
control
express
control
promot
plasmid
express
gfp
variant
cmv
immediateearli
promot
use
monitor
transfect
effici
transfect
perform
use
miru
reagent
mir
accord
manufactur
instruct
nfv
final
concentr
dmso
final
concentr
ad
cell
concurr
dna
transfect
reagent
cultur
incub
hour
chang
medium
time
cell
harvest
ice
scrape
ripa
buffer
contain
proteas
inhibitor
roch
complet
mini
edtafre
proteas
inhibitor
cocktail
tablet
protein
concentr
determin
bca
assay
pierc
extract
protein
glane
separ
sdspage
transfer
pvdf
membran
tank
transfer
overnight
blot
block
nonfat
dri
milk
probe
antiflag
mous
monoclon
antibodi
sigma
recogn
tag
scaffold
protein
antiha
monoclon
antibodi
clone
sigma
recogn
tag
human
foreskin
fibroblast
hff
mockinfect
infect
strain
f
moi
hour
inoculum
replac
medium
contain
dmso
nfv
hpi
medium
replac
mixtur
dmem
karnovski
fix
cultur
return
incub
minut
mixtur
replac
karnovski
cell
incub
minut
room
temperatur
cell
scrape
transfer
microcentrifug
tube
pellet
pellet
resuspend
ml
fix
dehydr
embed
section
affix
grid
accord
standard
method
grid
examin
jeol
jeol
jem
transmiss
electron
microscop
electron
microscopi
lab
fred
hutchinson
cancer
research
center
hff
seed
chamber
slide
confluenc
approxim
mockinfect
infect
moi
h
inoculum
replac
medium
dmso
nfv
cultur
return
incub
sixteen
hour
infect
cell
fix
paraformaldehyd
phosphatebuff
salin
cell
permeabil
endogen
peroxidas
activ
inhibit
h
cell
incub
nonfat
dri
milk
contain
normal
goat
serum
blottong
jackson
block
nonspecif
bind
primari
antibodi
bind
reveal
antimous
igghrp
jackson
follow
tsa
amplif
life
technolog
nuclei
stain
topro
slide
mount
addit
slowfad
life
technolog
analyz
confoc
microscopi
confoc
imag
gener
lsm
pascal
system
zeiss
passag
presenc
nfv
determin
resist
mutant
could
select
attempt
elucid
mechan
action
nfv
hhv
product
expect
multistep
passag
drug
pressur
readili
select
highlevel
resist
acyclovir
figur
contrast
signific
chang
suscept
nfv
observ
despit
parallel
passag
presenc
nfv
note
inhibitori
activ
nfv
differ
acyclovirresist
wild
type
isol
suggest
distinct
antivir
mechan
determin
nfv
aspartyl
proteas
inhibitor
could
act
essenti
serin
proteas
test
whether
nfv
could
inhibit
activ
proteas
scaffold
protein
substrat
use
cotransfect
assay
nfv
concentr
potent
block
product
infecti
effect
activ
proteas
express
cell
figur
attribut
decreas
akt
activ
one
promin
effect
nfv
human
cell
describ
inhibit
akt
signal
pathway
reduc
phosphoryl
akt
kinas
infect
result
increas
level
akt
phosphoryl
figur
previous
describ
akt
inhibitor
complet
suppress
akt
phosphoryl
infect
cell
nfv
reduc
level
phosphoryl
akt
even
drug
concentr
potent
block
viru
product
figur
furthermor
treatment
infect
hf
cell
reduc
product
infecti
viru
plaqu
assay
shown
consist
publish
data
therefor
unlik
document
inhibit
nfv
akt
activ
play
role
drug
inhibit
shown
kalu
et
al
support
preliminari
experi
data
shown
late
gene
express
hf
cell
reduc
nfv
treatment
therefor
explor
effect
nfv
infect
hf
cell
transmiss
electron
microscopi
normal
number
viru
particl
appear
produc
nfvtreat
cell
similar
number
capsid
observ
nucleu
untreat
nfvtreat
cell
approxim
resp
figur
b
howev
compar
untreat
cell
capsid
nfvtreat
cell
appear
disproportion
retain
within
cytoplasm
versu
proteas
figur
nfv
inhibit
activ
proteas
code
sequenc
fulllength
protein
product
orf
express
protein
employ
diagram
panel
transfect
vector
construct
express
proteas
ntermin
ha
tag
proteas
ntermin
flag
tag
substrat
mutant
inact
proteasescaffold
protein
ntermin
flag
tag
substrat
tag
depict
grey
left
end
construct
releas
r
matur
cleavag
site
shown
transfect
cell
construct
express
substrat
cleavag
evalu
western
blot
use
antiha
flag
antibodi
protein
express
alon
expect
size
kd
resp
includ
tag
similarli
coexpress
proteas
substrat
result
ntermin
cleavag
product
expect
size
gener
substrat
cleavag
product
affect
addit
nfv
concentr
inhibit
replic
vitro
resp
viru
particl
often
locat
outsid
plasma
membran
versu
suggest
block
viru
matur
egress
addit
contrast
cytoplasm
untreat
cell
cytoplasm
capsid
nfvtreat
cell
rare
observ
envelop
versu
field
shown
figur
c
interestingli
although
endoplasm
reticulum
er
stress
unfold
protein
respons
upr
autophagi
well
known
effect
nfv
neither
er
dilat
abund
doublemembran
bound
vesicl
consist
autophagosom
appear
consist
differ
nvftreat
untreat
cell
impair
nfv
evalu
glycoprotein
gb
gc
express
western
blot
appar
nfv
treatment
infect
cell
result
increas
electrophoret
mobil
figur
compar
untreat
control
idvtreat
cell
appar
chang
molecular
weight
viral
protein
estim
consist
reduct
glycosyl
assess
effect
nfv
protein
glycosyl
cell
eastern
blot
perform
use
lectin
pna
rcai
wga
cona
figur
compar
untreat
idvtreat
cell
nfv
result
mark
reduct
stain
pna
rcai
wga
indic
decreas
addit
galactos
nacetyldgalactosamin
nacetyldglucosamin
contrast
cona
stain
appreci
reduc
suggest
rel
normal
level
oligomannosetyp
nglycan
nfv
result
clear
alter
subcellular
local
gb
figur
b
immunofluoresc
antibodi
stain
compar
control
treatment
viral
envelop
glycoprotein
stain
uniformli
delin
plasma
membran
hf
cell
nfv
treatment
stain
appear
predominantli
perinuclear
suggest
improp
traffick
cell
surfac
consist
electron
microscopi
result
use
immunofluoresc
increas
stain
marker
autophagi
appar
data
shown
nfv
hiv
aspartyl
proteas
inhibitor
addit
antiretrovir
activ
complex
effect
numer
human
cellular
function
includ
akt
signal
inhibit
cellular
proteas
induct
er
stress
mani
might
contribut
abil
broadli
inhibit
tumor
cell
growth
well
replic
sever
nonhiv
virus
studi
specif
explor
mechan
nfv
might
inhibit
product
infecti
vitro
found
nfv
act
late
viru
product
without
detect
effect
late
viral
gene
express
furthermor
abund
viru
particl
observ
within
infect
cell
though
envelop
releas
viru
appear
substanti
diminish
consist
recent
publish
studi
kalu
et
al
also
report
nfv
block
matur
egress
nfv
show
activ
proteas
expect
given
serin
proteas
lack
structur
function
similar
hiv
aspartyl
proteas
shown
use
transfect
system
examin
enzymat
activ
tran
support
find
scaffold
protein
cleavag
appear
unaffect
cell
treat
nfv
resist
nfv
could
select
condit
readili
result
acyclovirresist
consist
find
kalu
et
al
though
nfvresist
may
well
isol
use
condit
find
suggest
rel
high
barrier
resist
vitro
suggest
mechan
action
host
cell
function
requir
viru
product
rather
direct
effect
viral
target
inde
mani
cellular
function
affect
nfv
similarli
describ
play
role
replic
nfv
inhibit
cellular
proteas
proteasom
lead
accumul
ineffici
remov
misfold
protein
er
golgi
find
nfv
result
impair
viral
protein
glycosyl
traffick
consist
process
valid
recent
find
kalu
et
al
note
base
cona
stain
nlinkag
immatur
high
mannos
carbohydr
appear
rel
normal
mannos
structur
larg
assembl
cytoplasm
wherea
trim
modif
complex
sugar
residu
occur
er
golgi
found
impair
viral
glycoprotein
process
least
one
mechan
nfv
reduc
infecti
product
agent
induc
er
stress
thapsigargin
similarli
interfer
glycoprotein
posttransl
process
product
infecti
viru
numer
studi
report
tunicamycin
block
synthesi
nacetylglucosaminelipid
intermedi
inhibitor
protein
glycosyl
decreas
infecti
yield
vitro
furthermor
tunicamycin
affect
level
late
viral
gene
product
express
normal
appear
capsid
note
within
cytoplasm
similar
effect
observ
nfv
unclear
howev
whether
impair
envelop
protein
glycosyl
would
block
viru
egress
base
studi
use
cell
line
defici
nacetylglucosaminyl
transferas
activ
viru
yield
mildli
reduc
work
sever
import
limit
effect
nfv
highli
pleiotrop
stress
nfv
might
affect
product
infecti
multipl
mechan
addit
base
known
nfv
effect
tumor
cell
relev
mechan
action
may
differ
respect
individu
hhv
cell
type
drug
concentr
necess
possibl
mechan
nfv
might
affect
replic
evalu
autophagi
catabol
process
maintain
cellular
homeostasi
condit
stress
promin
effect
nfv
encod
gene
block
autophagi
infect
cell
includ
infect
cell
protein
icp
requir
neurovirul
increas
level
autophagi
reduc
product
infecti
similarli
nfv
rel
normal
viral
gene
express
format
viral
particl
retain
within
cell
abl
formal
show
nfv
increas
autophagi
infect
cell
condit
use
nfv
treatment
appear
result
retent
cytoplasm
viru
particl
within
singl
membranebound
vesicl
could
late
autophagosom
report
howev
pathognomon
doublemembran
structur
convincingli
observ
greater
number
nfvtreat
versu
untreat
cell
abl
show
nfv
increas
stain
infect
autophagi
difficult
demonstr
current
exclud
potenti
contributor
effect
nfv
hhv
nfv
oral
bioavail
fdaapprov
treatment
hiv
infect
well
toler
longterm
use
sinc
advent
potent
conveni
option
nfv
longer
wide
prescrib
art
howev
activ
broad
rang
tumor
cell
type
intens
interest
reposit
nfv
cancer
chemotherapeut
agent
perhap
higher
dose
art
nfv
could
also
benefici
treatment
suppress
infect
hsv
hhv
particularli
set
resist
firstlin
antivir
patient
cancer
andor
hiv
addit
studi
indic
elucid
mechan
action
nfv
hhv
infect
evalu
efficaci
clinic
trial
